Sign up to save your podcasts
Or
Share The World in a Grain of Sand: Amylyx Pharmaceuticals
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The World in a Grain of Sand: Amylyx Pharmaceuticals
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:
the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab
Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor
Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy
and more
For updates from KdT, please subscribe to our Substack.
View all episodes
By KdT Ventures
5
1919 ratings
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:
the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab
Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor
Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy
and more
For updates from KdT, please subscribe to our Substack.
More shows like The World In A Grain Of Sand
View all
The Bill Simmons Podcast
30,131 Listeners
The Long Run with Luke Timmerman
116 Listeners
Business Of Biotech
84 Listeners